Associated autoimmune diseases in myasthenia gravis. A population-based study

Area of Science:

• Neurology
• Immunology
• Epidemiology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Associated autoimmune diseases (AAD) can coexist with MG, potentially influencing its course.
• Understanding the prevalence and impact of AAD in MG is crucial for patient management.

Purpose of the Study:

• To investigate the occurrence, clinical characteristics, and prognosis of AAD in a large cohort of MG patients.
• To determine if specific MG patient subgroups are at higher risk for developing AAD.
• To assess the impact of AAD and thymectomy on MG prognosis and remission rates.

Main Methods:

• A comprehensive epidemiological study was conducted in Western Denmark from 1975 to 1989.
• Incident and prevalent cases of myasthenia gravis were analyzed.
• Data on co-occurring autoimmune diseases, clinical features, and treatment outcomes were collected and evaluated.

Main Results:

• AAD were identified in 9% of incident and 14% of prevalent MG cases.
• Thyroid disorders and rheumatoid arthritis were the most common AAD.
• No clinical subgroup of MG patients demonstrated a significantly higher risk for AAD; AAD typically preceded thymectomy and did not influence its severity.
• MG patients with AAD exhibited a lower remission rate compared to those without AAD.

Conclusions:

• The presence of AAD in MG patients is associated with a poorer prognosis, indicated by lower remission rates.
• The autoimmune response in MG patients with coexisting AAD appears to be more severe.
• No identifiable clinical factors predict AAD development in MG patients, highlighting the systemic nature of autoimmunity in affected individuals.